Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors - PubMed
8 hours ago
- #oncogene-driven NSCLC
- #targeted therapy
- #PD-L1
- In driver gene-positive NSCLC patients with PD-L1 TPS ≥10%, those with TPS 10-49% had significantly better median PFS and OS compared to TPS ≥50%.
- First-line TKI therapy yielded superior median PFS (30.8 vs. 13.9 months) and OS (44.8 vs. 26.3 months) in the TPS 10-49% group versus TPS ≥50%.
- PD-L1 expression level did not significantly predict immunotherapy efficacy overall, but first-line immunotherapy benefited KRAS-mutant patients in PFS and OS.
- No significant clinical benefit from immunotherapy was observed among patients with high PD-L1 expression.
- In oncogene-driven NSCLC, PD-L1 expression is linked to targeted therapy efficacy but not predictive of immunotherapy response.